Which platelet function test best reflects the in vivo plasma concentrations of ticagrelor and its active metabolite?

Marek Koziński; Małgorzata Ostrowska; Piotr Adamski; Joanna Sikora; Adam Sikora; Aleksandra Karczmarska-Wódzka; Michat Piotr Marszał; Joanna Boinska; Ewa Laskowska; Ewa Obońska; Tomasz Fabiszak; Jacek Kubica

doi:10.1160/TH16-07-0535

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2016; 116(06): 1140-1149
DOI: 10.1160/TH16-07-0535

New Technologies, Diagnostic Tools and Drugs

Schattauer Publishers Schattauer

Which platelet function test best reflects the in vivo plasma concentrations of ticagrelor and its active metabolite?

The HARMONIC study

Marek Koziński

¹Department of Principles of Clinical Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

,

Małgorzata Ostrowska

¹Department of Principles of Clinical Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

,

Piotr Adamski

¹Department of Principles of Clinical Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

,

Joanna Sikora

²Department of Pharmacology and Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

,

Adam Sikora

³Department of Medicinal Chemistry, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

,

Aleksandra Karczmarska-Wódzka

²Department of Pharmacology and Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

,

Michat Piotr Marszał

¹Department of Principles of Clinical Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

,

Joanna Boinska

⁴Department of Pathophysiology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

,

Ewa Laskowska

¹Department of Principles of Clinical Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

,

Ewa Obońska

²Department of Pharmacology and Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

,

Tomasz Fabiszak

⁵Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

,

Jacek Kubica

⁵Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

› Author Affiliations

Abstract

Full Text

PDF Download

Keywords

Ticagrelor - AR-C124910XX - flow cytometric VASP-assay - VerifyNow device - Multiplate analyzer

References

References
1 Roffi M, Patrono C, Collet JP. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2016; 37: 267-315.
2 Steg PG, James SK, Atar D. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619.
3 Gurbel PA, Bliden KP, Butler K. et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopido-grel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120: 2577-2585.
4 Wallentin L, Becker RC, Budaj A. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
5 Aradi D, Kirtane A, Bonello L. et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 2015; 36: 1762-1771.
6 Aradi D, Storey RF, Komócsi A. et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 2014; 35: 209-215.
7 Aradi D, Collet JP, Mair J. et al. Platelet function testing in acute cardiac care - is there a role for prediction or prevention of stent thrombosis and bleeding?. Thromb Haemost 2015; 113: 221-230.
8 Tantry US, Bonello L, Aradi D. et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62: 2261-2273.
9 Storey RF, Angiolillo DJ, Bonaca MP. et al. Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 Trial. J Am Coll Cardiol 2016; 67: 1145-1154.
10 Which platelet function test best reflects the in vivo plasma concentrations of ti-cagrelor and its active metabolite? The HARMONIC study. ClinicalTrials.gov Identifier: NCT02690454 https://clinicaltrials.gov/ct2/show/NCT02690454?term=NCT02690454&rank=1 Accessed August 16, 2016.
11 Thygesen K, Alpert JS, Jaffe AS. et al. Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Eur Heart J 2012; 33: 2551-2567.
12 Kubica J, Adamski P, Ostrowska M. et al. Morphine delays and attenuates ti-cagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J 2016; 37: 245-252.
13 Koziński M, Obońska K, Stankowska K. et al. Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up. Cardiol J 2014; 21: 547-556.
14 Mangiacapra F, Patti G, Barbato E. et al. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYo-cardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. JACC Cardiovasc Interv 2012; 05: 281-289.
15 Bonello L, Mancini J, Pansieri M. et al. Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. J Thromb Haemost 2012; 10: 1999-2005.
16 Stone GW, Witzenbichler B, Weisz G. et al. ADAPT-DES Investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-elut-ing stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013; 382: 614-623.
17 Siller-Matula JM, Hintermeier A, Kastner J. et al. Distribution of clinical events across platelet aggregation values in all-comers treated with prasugrel and ti-cagrelor. Vascul Pharmacol 2016; 79: 6-10.
18 Alexopoulos D, Stavrou K, Koniari I. et al. Ticagrelor vs prasugrel one-month maintenance therapy: impact on platelet reactivity and bleeding events. Thromb Haemost 2014; 112: 551-557.
19 Windecker S, Kolh P, Alfonso F. et al. 2014 ESC/EACTS Guidelines on myo-cardial revascularization. Eur Heart J 2014; 35: 2541-2619.
20 Price MJ, Berger PB, Teirstein PS. et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. J Am Med Assoc 2011; 305: 1097-1105.
21 Trenk D, Stone GW, Gawaz M. et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012; 59: 2159-2164.
22 Collet JP, Cuisset T, Rangé G. et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367: 2100-2109.
23 Bouman HJ, Parlak E, van Werkum JW. et al. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost 2010; 08: 482-488.
24 Liang Y, Johnston M, Hirsh J. et al. Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopi-dogrel and aspirin. J Thromb Thrombolysis 2012; 34: 429-436.
25 Delavenne X, Mallouk N, Piot M. et al. Is there really a relationship between the plasma concentration of the active metabolite of clopidogrel and the results of platelet function tests?. J Thromb Haemost 2010; 08: 2334-2338.
26 Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable angina, NSTEMI and STEMI undergoing PCI. ClinicalTrials.gov Identifier: NCT02012140 https://clinicaltrials.gov/ct2/show/NCT02012140?term=NCT02012140&rank=1 Accessed August 16, 2016.
27 Comparison of ticagrelor pharmacokinetics and pharmacodynamics in STEMI and NSTEMI patients (PINPOINT). ClinicalTrials.gov Identifier: NCT02602444 https://clinicaltrials.gov/ct2/show/NCT02602444?term=NCT02602444&rank=1 Accessed August 16, 2016.
28 Alexopoulos D, Xanthopoulou I, Gkizas V. et al. Randomized assessment of ti-cagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elev-ation myocardial infarction. Circ Cardiovasc Interv 2012; 05: 797-804.
29 Parodi G, Valenti R, Bellandi B. et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013; 61: 1601-1606.

Supplementary Material

Online Supplementary Material (PDF)